CJC-1295 (with Drug Affinity Complex, DAC) is a synthetic growth hormone–releasing hormone (GHRH) analog extensively studied in laboratory and preclinical research for its role in prolonged growth hormone (GH) signaling and sustained endocrine pathway activation. CJC-1295 (w/ DAC) 5mg is commonly utilized in controlled research environments to evaluate extended GH release dynamics, insulin-like growth factor-1 (IGF-1) modulation, and hypothalamic–pituitary axis regulation.
 
The DAC modification enables prolonged half-life through reversible binding to serum albumin, allowing for extended receptor engagement and continuous stimulation of GH pathways in experimental models. Research applications frequently focus on long-acting GH pulsatility, metabolic regulation, tissue repair signaling, and age-related endocrine function studies.
 
Additional investigations explore its role in body composition signaling, recovery pathway research, and systemic metabolic efficiency. Due to its extended-activity profile, CJC-1295 (w/ DAC) is frequently selected in studies requiring sustained GH pathway activation compared to short-acting GHRH analogs.
This high-purity 5mg formulation is manufactured to strict laboratory standards and intended exclusively for analytical testing, in-vitro studies, and experimental research applications.
 
For research use only. Not for human consumption.
 
See product pictures for Certificate of Analysis.